Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients
Corresponding Author
Andrew M. South
Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA
Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston Salem, NC, USA
Correspondence
Andrew M. South, Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA.
Email: [email protected]
Search for more papers by this authorLynn Maestretti
Pediatric Renal Transplant Program, Lucile Packard Children's Hospital at Stanford, Stanford, CA, USA
Search for more papers by this authorNeeraja Kambham
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorPaul C. Grimm
Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorAbanti Chaudhuri
Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorCorresponding Author
Andrew M. South
Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA
Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston Salem, NC, USA
Correspondence
Andrew M. South, Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC, USA.
Email: [email protected]
Search for more papers by this authorLynn Maestretti
Pediatric Renal Transplant Program, Lucile Packard Children's Hospital at Stanford, Stanford, CA, USA
Search for more papers by this authorNeeraja Kambham
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorPaul C. Grimm
Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorAbanti Chaudhuri
Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
Search for more papers by this authorAbstract
Pediatric renal transplant recipient survival continues to improve, but ABMR remains a significant contributor to graft loss. ABMR prognostic factors to guide treatment are lacking. C4d staining on biopsies, diagnostic of ABMR, is associated with graft failure. Persistent C4d+ on follow-up biopsies has unknown significance, but could be associated with worse outcomes. We evaluated a retrospective cohort of 17 pediatric renal transplant patients diagnosed with ABMR. Primary outcome at 12 months was a composite of ≥50% reduction in eGFR, transplant glomerulopathy, or graft failure. Secondary outcome was the UPCR at 12 months. We used logistic and linear regression modeling to determine whether persistent C4d+ on follow-up biopsy was associated with the outcomes. Forty-one percent reached the primary outcome at 12 months. Persistent C4d+ on follow-up biopsy occurred in 41% and was not significantly associated with the primary outcome, but was significantly associated with the secondary outcome (estimate 0.22, 95% CI 0.19-0.25, P < .001), after controlling for confounding factors. Persistent C4d+ on follow-up biopsies was associated with a higher UPCR at 12 months. Patients who remain C4d+ on follow-up biopsy may benefit from more aggressive or prolonged ABMR treatment.
Supporting Information
Filename | Description |
---|---|
petr13035-sup-0001-TableS1.docxWord document, 19.8 KB | |
petr13035-sup-0002-TableS2.docxWord document, 15.9 KB | |
petr13035-sup-0003-TableS3.docxWord document, 17.8 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280: 735-739.
- 2Delmonico FL, Fuller A, Cosimi B, Tolkoff-Rubin N, Al E. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation. 1983; 36: 629-633.
- 3Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Al E. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol. 2013; 24: 655-664.
- 4Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9: 2520-2531.
- 5Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant. 2008; 8: 1367-1373.
- 6Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14: 272-283.
- 7Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. 2014; 19: 315-322.
- 8Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993; 43: 1333-1338.
- 9Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010; 90: 68-74.
- 10Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001; 59: 334-341.
- 11Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011; 11: 56-65.
- 12Sapir-Pichhadze R, Curran SP, John R, et al. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2015; 87: 182-194.
- 13Kikić Ž, Kainz A, Kozakowski N, et al. Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol. 2015; 10: 1435-1443.
- 14Valente M, Furian L, Della Barbera M, et al. Glomerular C4d immunoreactivity in acute rejection biopsies of renal transplant patients. Transpl Proc. 2012; 44: 1897-1900.
- 15Hayde N, Bao Y, Pullman J, et al. The clinical and molecular significance of C4d staining patterns in renal allografts. Transplantation. 2013; 95: 580-588.
- 16Archdeacon P, Chan M, Neuland C, Al E. Summary of FDA antibody-mediated rejection workshop. Am J Transplant. 2011; 11: 896-906.
- 17Loupy A, Haas M, Solez K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017; 17: 28-41.
- 18Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20: 629-637.
- 19Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983; 309: 1543-1546.
- 20Steinhäuslin F, Wauters JP. Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. Clin Nephrol. 1995; 43: 110-115.
- 21Borrego Hinojosa J, Gentil Govantes MA, Cabello Díaz M, et al. Progression of urinary protein excretion after kidney transplantation: a marker for poor long-term prognosis. Nefrologia. 2015; 35: 374-384.
- 22Moranne O, Maillard N, Fafin C, Thibaudin L, Alamartine E, Mariat C. Rate of renal graft function decline after one year is a strong predictor of all-cause mortality. Am J Transplant. 2013; 13: 695-706.
- 23Morales JM, Marcén R, Del Castillo D, et al. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012; 27: iv39-iv46.
- 24Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012; 81: 628-639.
- 25Kanetsuna Y, Yamaguchi Y, Horita S, Tanabe K, Toma H. C4d and/or immunoglobulins deposition in peritubular capillaries in perioperative graft biopsies in ABO-incompatible renal transplantation. Clin Transplant. 2004; 18: 13-17.
- 26Haas M, Segev DL, Racusen LC, et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol. 2009; 20: 197-204.
- 27Immenschuh S, Zilian E, Dämmrich ME, et al. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation. Transplantation. 2015; 99: 56-62.
- 28Matignon M, Muthukumar T, Seshan SV, Suthanthiran M, Hartono C. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d positive antibody-mediated rejection. Transplantation. 2012; 94: 603-611.
- 29Willicombe M, Roufosse C, Brookes P, et al. Acute cellular rejection: impact of donor-specific antibodies and C4d. Transplantation. 2014; 97: 433-439.
- 30Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2011; 16: 12-17.
- 31Loupy A, Lefaucheur C, Vernerey D, Prugger C, Al E. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369: 1215-1226.
- 32Ghata J, Sindhwani P, Lewis T, Turman M. Treatment of late onset de novo donor specific antibody (DSA)-mediated pediatric kidney transplant rejection with bortezomib [abstract]. Am J Transplant. 2013; 13(Suppl 5). http://atcmeetingabstracts.com/abstract/treatment-of-late-onset-de-novo-donor-specific-antibody-dsa-mediated-pediatric-kidney-transplant-rejection-with-bortezomib/.
- 33Gulleroglu KK, Baskin E, Bayrakci US, et al. Antibody-mediated rejection and treatment in pediatric patients: one center's experience. Exp Clin Transplant. 2013; 11: 404-407.
- 34Pape L, Becker J, Immenschuh S, Ahlenstiel T. Acute and chronic antibody-mediated rejection in pediatric kidney transplantation. Pediatr Nephrol. 2015; 30: 417-424.
- 35Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplant. Am J Transplant. 2008; 8: 2607-2617.